In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
Commentary|Articles|May 7, 2026
ASCO 2026 TNBC Deep Dive: Breast Cancer Experts Preview Practice-Informing Studies
Author(s)Ashling Wahner
Fact checked by: Chris Ryan
Experts spotlight the triple-negative breast cancer abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.
Advertisement
Advertisement
As conversations continue around the
Related to this article
The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Dostarlimab monotherapy produced a 27% response rate in PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma
Read a refresh of breast cancer FDA news from July, including the first approval of a pan-PI3K/mTOR inhibitor combination and a pegfilgrastim biosimilar.
Breast cancer experts share insights on how recently approved indications for 3 ADCs will affect clinical practice.
Durable outcomes were reported standard-dose tivozanib monotherapy in second- and third-line metastatic RCC.
Advertisement
Advertisement